I

InterCure Ltd
TASE:INCR

Watchlist Manager
InterCure Ltd
TASE:INCR
Watchlist
Price: 504.1 ILS -0.24% Market Closed
Market Cap: 242.4m ILS
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one INCR stock under the Base Case scenario is 728.17 ILS. Compared to the current market price of 504.1 ILS, InterCure Ltd is Undervalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INCR Relative Value
Base Case
728.17 ILS
Undervaluation 31%
Relative Value
Price
I
Worst Case
Base Case
Best Case

Valuation Multiples

0.7
P/S
P/S
Price to Sales
0.7
vs History
87
vs Industry
76
Median 3Y
0.9
Median 5Y
1.6
Industry
2.5
Forward
0.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
20
Median 3Y
-3.6
Median 5Y
10
Industry
21.8
Forward
8.7
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
46
Median 3Y
-5.3
Median 5Y
-4.6
Industry
16.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
24
Median 3Y
-1.9
Median 5Y
-2
Industry
24
More Details
0.5
P/B
P/B
Price to Book Value
0.5
vs History
88
vs Industry
72
Median 3Y
0.7
Median 5Y
1.2
Industry
2.1
More Details
0.7
EV/S
EV/S
Enterprise Value to Sales
0.7
vs History
87
vs Industry
78
Median 3Y
0.9
Median 5Y
1.6
Industry
2.7
Forward
0.6
More Details
2.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.3
vs History
80
vs Industry
66
Median 3Y
2.6
Median 5Y
4.3
Industry
5.3
More Details
5.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.4
vs History
69
vs Industry
45
Median 3Y
6.3
Median 5Y
6.6
Industry
12.8
Forward
5.1
More Details
7.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.7
vs History
61
vs Industry
42
Median 3Y
8.6
Median 5Y
8.9
Industry
16.2
Forward
4.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
46
Median 3Y
-5.3
Median 5Y
-4.6
Industry
15.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
31
Median 3Y
-6.9
Median 5Y
-6.2
Industry
17.7
More Details
0.4
EV/IC
EV/IC
Enterprise Value to IC
0.4
vs History
88
vs Industry
75
Median 3Y
0.6
Median 5Y
1
Industry
1.9
More Details

Multiples Across Competitors

INCR Competitors Multiples
InterCure Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
InterCure Ltd
TASE:INCR
242.4m ILS 0.7 -3.9 5.4 7.7
US
Eli Lilly and Co
NYSE:LLY
743.9B USD 15.2 67.1 36 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
374.6B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.5 18.8 13 15
CH
Roche Holding AG
SIX:ROG
205.3B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
191.2B CHF 4.5 18.7 11 14.7
UK
AstraZeneca PLC
LSE:AZN
160.1B GBP 4 28 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
209B USD 3.3 12 8.9 10.8
IE
Endo International PLC
LSE:0Y5F
185.4B USD 79.9 -63.4 294.8 739.4
US
Pfizer Inc
NYSE:PFE
144.5B USD 2.3 18.4 7.8 11
P/E Multiple
Earnings Growth PEG
IL
I
InterCure Ltd
TASE:INCR
Average P/E: 25.6
Negative Multiple: -3.9 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67.1
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.8
18%
1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
18.7
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -63.4 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.4
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
I
InterCure Ltd
TASE:INCR
Average EV/EBITDA: 397.8
5.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
11
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.9
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
294.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IL
I
InterCure Ltd
TASE:INCR
Average EV/EBIT: 1 705.9
7.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.7
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.8
11%
1
IE
E
Endo International PLC
LSE:0Y5F
739.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
11
10%
1.1

See Also

Summary
INCR intrinsic value, competitors valuation, and company profile.
DCF Valuation
INCR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
INCR stock valuation using valuation multiples.
Wall Street Estimates
INCR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
INCR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 266,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.